Home › Blog › Weight Loss › Mounjaro NHS

Mounjaro NHS 2026: The Complete Guide — Eligibility, the April QOF Update, Waiting Times and What to Do If You Don’t Qualify

Overview: Mounjaro on the NHS in 2026

Mounjaro (tirzepatide) was approved for NHS prescribing in England following NICE TA1026 in 2025. The rollout began on 23 June 2025. By April 2026, the programme had undergone a significant structural change — being incorporated into the NHS GP contract through Quality and Outcomes Framework (QOF) indicators. And from June 2026, the eligibility threshold is expanding to include patients with BMI 35 or above.

This is the most current, most complete Mounjaro NHS guide available — updated to reflect the April 2026 QOF change that most other guides have not yet covered, and the June 2026 threshold expansion that is just beginning to roll out.

The honest picture is this: NHS Mounjaro access is improving, but remains very restricted for most patients. Fewer than 15,000 patients received NHS-funded Mounjaro in year one (BMJ FOI data, 2025). The majority of the 2 million+ UK adults currently using weight loss injections are paying privately. This guide helps you understand exactly where you sit in the eligibility landscape — and what your options are if you do not currently qualify.

The April 2026 QOF Update: What Actually Changed

The most significant and least-reported development in NHS Mounjaro access in 2026 is the Quality and Outcomes Framework (QOF) incorporation that took effect from 1 April 2026. Understanding what QOF is and what changed explains a great deal about how NHS Mounjaro prescribing now works in practice.

What is QOF?

The Quality and Outcomes Framework is the annual incentive programme for GP practices in England. It sets out clinical indicators that practices are expected to meet, covering areas including diabetes management, cardiovascular disease prevention, and chronic disease management. GP practices earn payments for meeting these indicators — it is the primary mechanism through which NHS England encourages GPs to adopt new clinical practices.

What changed from 1 April 2026

From 1 April 2026, NHS England incorporated prescribing of tirzepatide (Mounjaro) for obesity into the 2026/27 GP contract through new QOF indicators. This means:

• GP practices receive financial incentives for identifying eligible patients and prescribing Mounjaro through the appropriate pathway
• Prescribing responsibility shifted — from a purely specialist tier 3 model to one where GP practices can earn QOF points for supporting access
• GP participation is not mandated — practices can choose whether to participate in the QOF obesity prescribing indicators, so availability varies by surgery
• For type 2 diabetes — QOF now recognises GLP-1 and dual GIP/GLP-1 agonists like tirzepatide, meaning GPs can prescribe Mounjaro for type 2 diabetes in primary care under updated QOF incentives (this is separate from the weight management pathway)

What has NOT changed

The QOF update does not mean GPs can now freely prescribe Mounjaro for weight loss to any patient who asks. The prescribing criteria — BMI thresholds, qualifying conditions — remain in force. The change is about the mechanism for GP involvement, not the eligibility thresholds. Patients who do not meet the criteria are still not eligible for NHS Mounjaro, regardless of which GP practice they are registered with.

Who Qualifies for NHS Mounjaro Right Now (June 2026)

Here is the current eligibility picture as of June 2026, reflecting the phase 1 criteria that apply since the June 2025 rollout and through to the June 2026 expansion.

Phase 1 criteria (23 June 2025 — ongoing for some areas)

The June 2026 Expansion: BMI 35 Threshold

From approximately June 2026 — the timeline is rolling out across different ICBs at different speeds — the NHS Mounjaro eligibility threshold is expanding. This is the change that will significantly broaden access for the first time since the rollout began.

Phase 2 criteria (from June 2026 — rolling out by ICB)

How much does this change?

Reducing the BMI threshold from 40 to 35 while maintaining the four-condition requirement significantly expands the eligible population. Patients with BMI 35–39.9 and four qualifying conditions — who were previously excluded entirely — now become eligible. Exact numbers are not yet published, but NHS England estimates suggest the phase 2 eligible population is approximately two to three times larger than phase 1.

March 2027: The Next Expansion

The NICE TA1026 commissioning framework sets out planned further expansions beyond June 2026. The next significant threshold change is anticipated from approximately March 2027:

The Full 12-Year NHS Mounjaro Rollout: Timeline and Trajectory

How to Access NHS Mounjaro: The Process Explained

If you believe you meet the current eligibility criteria, here is how the NHS Mounjaro access process works.

Step 1: Check your eligibility

Review the eligibility criteria above honestly. You need to meet BOTH the BMI threshold AND have at least four (phase 1 and 2) or three (phase 3 onwards) of the five qualifying conditions. Many patients believe they qualify when they do not — particularly on the number of qualifying conditions.

Step 2: Do not self-refer

NHS England guidance is explicit: patients do not apply for NHS Mounjaro — eligible individuals are identified through GP records and contacted, or assessed when they present to their GP. The NHS has specifically asked people not to contact their GP to request Mounjaro by name, as local prescribing hubs manage the allocation process.

Step 3: Speak to your GP — but approach it correctly

The guidance not to request Mounjaro by name does not mean you cannot discuss weight management with your GP. The right approach is to:

• Tell your GP you are concerned about your weight and the health conditions it is affecting
• Ask what weight management services and treatments are available locally
• Ask whether you might be eligible for NHS weight management medication given your BMI and health conditions
• Ask specifically about the NHS tier 3 weight management referral pathway in your area

Step 4: Tier 3 referral

If your GP assesses you as potentially eligible, they will refer you to a specialist tier 3 weight management service. This is a multidisciplinary service including dieticians, psychologists, and specialist prescribers. The service will conduct a full clinical assessment and, if eligible, prescribe Mounjaro alongside lifestyle support.

Step 5: Waiting list

Most tier 3 services have significant waiting lists — typically 12–24 months in most areas of England. See the waiting times section below.

Talking to Your GP About Mounjaro: The Right Script

Many patients find that their GP is either unaware of the current NHS Mounjaro eligibility criteria or uncertain about the referral pathway. Here is how to have a productive conversation.

What to say

“I’d like to talk about my weight and how it’s affecting my health. I have [conditions]. I understand there are now NHS-funded medications for obesity — I wanted to ask whether I might be eligible and what the referral pathway looks like in this area.”

What to bring to the appointment

• Recent blood pressure readings (if you have them)
• Recent blood test results showing HbA1c, cholesterol, or other relevant markers
• Your BMI calculation or recent weight measurement
• A list of all qualifying conditions you have been diagnosed with

What to ask

• “Has our ICB started the phase 2 expansion (BMI 35+) for NHS Mounjaro?”
• “Is our practice participating in the new QOF obesity prescribing indicators?”
• “What is the tier 3 weight management referral pathway in this area and what is the current waiting time?”
• “Would I be eligible based on my current BMI and conditions?”

Waiting Times by Region

One of the most significant practical barriers to NHS Mounjaro access is waiting time for tier 3 weight management services. Waiting times vary enormously by Integrated Care Board area — from months in some well-resourced areas to 2+ years in others.

Scotland, Wales and Northern Ireland

NHS Mounjaro access outside England follows different pathways because health is a devolved responsibility.

NHS Wegovy — The Alternative NHS Route

For patients who do not meet NHS Mounjaro criteria, NHS Wegovy (semaglutide) provides an alternative NHS pathway — with different eligibility criteria.

Private Mounjaro as a Clinical Bridge

For patients who meet clinical eligibility (BMI 30+, one qualifying condition) but not NHS eligibility (BMI 35–40+, four conditions), private Mounjaro through a GPhC-regulated provider like Slinic is an appropriate and safe route — and not incompatible with NHS waiting list status.

Key clinical considerations

• Starting private does not affect your NHS waiting list position — you can be on an NHS tier 3 waiting list and access private Mounjaro simultaneously. If your NHS place comes through, you simply transition to NHS supply.
• The medication is identical — NHS and private Mounjaro is the same MHRA-licensed Eli Lilly tirzepatide. The difference is the prescribing pathway and cost, not the medication.
• Clinical progress on private treatment counts — weight loss achieved privately is clinically meaningful regardless of the funding route. You do not need to stop and restart when you transition to NHS.
• Tell your GP — your GP should know you are taking Mounjaro privately. It affects blood sugar, blood pressure, and the absorption of some other medications. It is also useful information for your NHS tier 3 referral.

NHS vs Private Mounjaro: The Full Comparison

When to prioritise NHS access

• You meet the strict eligibility criteria (BMI 35+ currently, or 40+ in phase 1 areas)
• You can wait 12–24 months without significant clinical detriment
• Cost is a prohibitive barrier to private access
• You want the full multidisciplinary support of a tier 3 service

When to consider private access

• You do not currently meet NHS eligibility criteria
• You cannot or do not want to wait 12–24 months
• Your condition is progressive and delay represents a clinical risk (worsening blood sugar, blood pressure, joint damage)
• You want to start now and transition to NHS when your place becomes available

What NHS Mounjaro Monitoring Looks Like vs Private

A practical question many patients ask is what monitoring they can expect — and whether it differs between NHS and private Mounjaro.

NHS tier 3 monitoring

NHS tier 3 services follow a structured monitoring protocol that includes weight measurement at every appointment, blood pressure monitoring, blood glucose and HbA1c (particularly for patients with diabetes or pre-diabetes), lipid profile at baseline and follow-up, and annual review including assessment of whether clinical benefit justifies continuation. Liver function and kidney function may also be monitored where clinically indicated. This monitoring is systematic, protocol-driven, and multidisciplinary.

Slinic monitoring

At Slinic, every patient receives a free monthly clinical check-in with a registered prescriber. This covers weight progress, side effect assessment, dose management and escalation approval, dietary and nutritional adequacy review, and any clinical concerns. We recommend patients also maintain contact with their GP for any annual blood test monitoring — HbA1c for patients with diabetes or pre-diabetes, blood pressure for hypertensive patients, and lipid profiles where relevant. For patients on levothyroxine or blood pressure medication, we actively liaise on potential dose adjustments as clinical markers improve.

The Future of NHS Mounjaro: What Patients Should Watch For

NHS Mounjaro access is on a defined expansion trajectory. Here is what to watch for over the next 12–24 months that could change the picture significantly.

• March 2027 phase 3 expansion — planned reduction from four to three required qualifying conditions at BMI 40+ and 35+. This could bring a large additional patient population into NHS eligibility.
• NICE appraisal of retatrutide — if and when retatrutide (28.3% average weight loss in TRIUMPH-1) receives MHRA approval, NICE will need to appraise it. This may accelerate the overall NHS obesity pharmacotherapy landscape and create political pressure to expand Mounjaro access more quickly.
• NHS Wegovy 7.2mg tier 3 rollout — NICE has not yet approved the 7.2mg dose for NHS. When it does, NHS Wegovy patients may be able to step up to the higher dose, potentially producing outcomes closer to NHS Mounjaro.
• Wegovy pill NHS appraisal — MHRA approved the Wegovy pill on 11 June 2026. NICE will need to conduct a technology appraisal before NHS coverage. This is typically a 12–18 month process from MHRA approval.
• GP QOF uptake data — as 2026/27 QOF data emerges, it will become clear how many GP practices are participating in the new Mounjaro prescribing indicators and how rapidly the T2D pathway is being used.

For the most current NHS Mounjaro developments, bookmark this page — it is updated quarterly as NHS commissioning guidance evolves. And for patients who cannot wait for NHS access, Slinic offers the same medication from £139 with no waiting list.

NHS Mounjaro for Type 2 Diabetes: A Different and Faster Pathway

One of the least-known aspects of the April 2026 QOF update is that it creates a potentially faster NHS Mounjaro pathway for patients with type 2 diabetes — separate from the obesity weight management route.

Mounjaro (tirzepatide) is licensed in the UK for both weight management and type 2 diabetes management. The diabetes licence has existed since the MHRA approved Mounjaro for T2D in 2022 — before the obesity weight management approval in 2023. Under the April 2026 QOF changes, GP practices are now incentivised to consider GLP-1 and dual GIP/GLP-1 agonists (including tirzepatide) for patients with type 2 diabetes in primary care.

What this means practically

• A patient with type 2 diabetes and a BMI above the private prescribing threshold may be able to access NHS Mounjaro through their GP’s diabetes prescribing pathway — without going through tier 3 weight management services
• The GP QOF indicators for diabetes now recognise the dual benefit of tirzepatide for blood sugar control and weight reduction
• This pathway is primarily for glycaemic control rather than weight management as the primary indication — but the weight loss benefit is a recognised secondary outcome
• GP participation in the QOF diabetes indicators is not mandatory — check with your specific practice

Regional ICB Variation: Why Your Postcode Matters

One of the most practically important but least-discussed aspects of NHS Mounjaro access is the enormous variation between Integrated Care Board areas. The same patient with the same BMI and the same conditions can face very different access timelines depending purely on where they live.

Why ICB variation exists

NHS England sets the national eligibility framework through NICE TA1026 — but implementation is devolved to the 42 ICBs across England. Each ICB makes its own decisions about:

• Which tier 3 services to commission and at what capacity
• Whether to adopt the QOF Mounjaro indicators in primary care
• The pace of the phase 2 (BMI 35+) expansion within their area
• Whether to commission community weight management services (as NHS Cheshire and Merseyside did early)

The result is a postcode lottery — a patient in Cheshire and Merseyside may access NHS Mounjaro significantly faster than an equivalent patient in a rural ICB with lower tier 3 commissioning capacity.

How to find out your ICB’s position

• Ask your GP directly: “Has our ICB started the phase 2 expansion for NHS Mounjaro?”
• Check your local ICB website — most publish their medicines commissioning policies
• Contact your ICB’s patient services team
• Check NHS England’s published commissioning guidance for your region

What Happens During NHS Mounjaro Treatment

For patients who do access NHS Mounjaro through the tier 3 pathway, understanding what the treatment experience looks like is important for setting expectations.

The tier 3 multidisciplinary team

Unlike private Mounjaro — where treatment is primarily clinician-prescriber led — NHS tier 3 weight management services are multidisciplinary. Your team typically includes:

• Specialist prescriber — doctor, nurse prescriber, or pharmacist prescriber who conducts clinical assessment and issues prescriptions
• Dietitian — nutritional assessment and dietary guidance throughout treatment
• Psychologist or behaviour change specialist — addressing the psychological dimensions of weight management
• Physiotherapist or exercise specialist — physical activity guidance and support

This multidisciplinary model provides a level of wraparound support that even the best private providers cannot match at the price point. For patients who access NHS Mounjaro, the clinical support structure is a genuine additional benefit beyond the cost saving.

Review schedule

NHS tier 3 services typically conduct reviews at:

• Month 1 — tolerability and initiation assessment
• Month 3 — early progress review
• Month 6 — mid-treatment assessment and dose optimisation
• Month 12 — annual review and continuation decision

Continuation of NHS Mounjaro is typically subject to achieving a minimum weight loss threshold at each review — generally 5% of starting body weight at 3 months is the minimum expected response. Patients who do not achieve this may have their treatment reviewed.

Full Scenario Analysis: Should You Wait for NHS or Start Private?

The right answer depends entirely on your individual circumstances. Here are five common patient scenarios and the most appropriate course of action for each.

Scenario 1: BMI 42, four qualifying conditions, can wait

Recommendation: Pursue NHS access. You meet phase 1 criteria. Your GP should be able to refer you to tier 3 services. The 12–18 month wait is significant but the cost saving (£9.90 vs £285/month) over a 12-month course is approximately £3,390. If you can manage your conditions with existing medications during the wait without clinical detriment, NHS is the right route.

Scenario 2: BMI 38, two qualifying conditions, progressive conditions

Recommendation: Start private now. You don’t meet NHS criteria (need BMI 35+ with FOUR conditions). You are clinically eligible for private Mounjaro (BMI 30+ with one condition). Your conditions are progressive — every month without treatment potentially worsens your metabolic profile. Start at Slinic from £139/pen now. Get on NHS tier 3 waiting list simultaneously if you want future NHS access.

Scenario 3: BMI 36, four qualifying conditions, June 2026 phase 2 area

Recommendation: Pursue NHS and start private simultaneously. You now meet phase 2 criteria if your ICB has implemented it. Ask your GP about tier 3 referral immediately. But tier 3 waiting times in most areas are still 12–24 months. Starting private Mounjaro now is compatible with being on the NHS waiting list. You get clinical benefit immediately and transition to NHS supply when available.

Scenario 4: BMI 33, type 2 diabetes, no other conditions

Recommendation: Ask your GP about the diabetes QOF pathway. You have type 2 diabetes — ask your GP specifically about prescribing tirzepatide for your diabetes management under the April 2026 QOF indicators. This may be a faster NHS route than the tier 3 obesity pathway. If your GP can’t prescribe it, private Mounjaro at Slinic (BMI 30+ with T2D qualifies) is immediately available.

Scenario 5: BMI 31, no qualifying conditions, cost is a concern

Recommendation: Private Wegovy may be a better option. You qualify for private prescribing (BMI 30+) but NHS access is many years away. Consider Wegovy starting from £99.99/pen at Slinic rather than Mounjaro at £139 — meaningfully cheaper while producing 14.9–20.7% average weight loss. See our Mounjaro vs Wegovy guide.

Full Cost Comparison: NHS vs Private Over 12 Months

The cost saving of NHS Mounjaro over private is substantial — approximately £2,995/year compared with private Mounjaro at Slinic. But this saving only materialises if you actually receive NHS treatment. For the majority of patients who do not currently meet the strict eligibility criteria, or who cannot wait 12–24 months, private access remains the only practical route.

Frequently Asked Questions

NHS Prescription Charges and Exemptions for Mounjaro

If you receive NHS Mounjaro, you pay the standard NHS prescription charge unless you are exempt. Understanding the charge and exemptions is important for cost planning.

Standard charge

The standard NHS prescription charge in 2026 is £9.90 per item. Each Mounjaro KwikPen is one prescription item. You pay £9.90 per pen regardless of dose — whether 2.5mg or 15mg. Over a 12-month course requiring 12 pens, this totals approximately £118.80.

Who is exempt from prescription charges?

• Children under 16, or under 19 and in full-time education
• Adults aged 60 or over
• Patients with certain medical conditions (including diabetes with an exemption certificate, hypothyroidism)
• Patients receiving certain benefits (Universal Credit, income support, others)
• Pregnant women and women who have had a baby in the last 12 months (with a maternity exemption certificate)

Prescription Prepayment Certificates (PPC)

If you pay prescription charges and take regular NHS medication, a Prescription Prepayment Certificate (PPC) caps your charges. For 2026:

• 3-month PPC: approximately £32.05 — covers unlimited prescriptions for 3 months
• 12-month PPC: approximately £114.50 — covers unlimited prescriptions for 12 months

A 12-month PPC at £114.50 covers all 12 Mounjaro pens plus all other NHS prescriptions for the year — potentially saving money if you receive other regular prescription items.

Check if you qualify for free prescriptions

Check your exemption status at nhs.uk before paying prescription charges. Many patients with diabetes, thyroid conditions, or receiving certain benefits qualify for free prescriptions and may not realise it.

References

1. NICE TA1026 — Tirzepatide for managing overweight and obesity. 2025.
2. NHS England. Weight management injections — Mounjaro rollout guidance.
3. NHS Cheshire and Merseyside ICB. Mounjaro (tirzepatide) prescribing guidance — QOF April 2026 update.
4. BMJ Freedom of Information investigation. NHS Mounjaro rollout — ICB prescribing data. 2025.
5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
6. NICE TA875 — Semaglutide for managing overweight and obesity. 2023.
7. GPhC guidance for online pharmacies. Updated February 2025. pharmacyregulation.org

Related Guides